Smart Nanofiber Mesh with Locally Sustained Drug Release Enabled Synergistic Combination Therapy for Glioblastoma

Yinuo Li; Yoshitaka Matsumoto; Lili Chen; Yu Sugawara; Emiho Oe; Nanami Fujisawa; Mitsuhiro Ebara; Hideyuki Sakurai

Article Smart Nanofiber Mesh with Locally Sustained Drug Release Enabled Synergistic Combination Therapy for Glioblastoma

Yinuo Li ; Yoshitaka Matsumoto ; Lili Chen (National Institute for Materials Science) ; Yu Sugawara ; Emiho Oe (National Institute for Materials Science) ; Nanami Fujisawa (National Institute for Materials Science) ; Mitsuhiro Ebara (National Institute for Materials Science) ; Hideyuki Sakurai

Download all files
(954 KB)

Collection

Citation

Yinuo Li, Yoshitaka Matsumoto, Lili Chen, Yu Sugawara, Emiho Oe, Nanami Fujisawa, Mitsuhiro Ebara, Hideyuki Sakurai. Smart Nanofiber Mesh with Locally Sustained Drug Release Enabled Synergistic Combination Therapy for Glioblastoma. Nanomaterials. 2023, 13 (3), 414.

(BibTeX)

Description:

(abstract)

This study aims to propose a new treatment model for glioblastoma (GBM). The combination of chemotherapy, molecular targeted therapy and radiotherapy has been achieved in a highly simultaneous manner through the application of a safe, non-toxic, locally sustained drug-releasing composite Nanofiber mesh (NFM). The NFM consisted of biodegradable poly(ε-caprolactone) with temozolomide (TMZ) and 17-allylamino-17-demethoxygeldanamycin (17AAG), which was used in radiation treatment. TMZ and 17AAG combination showed a synergistic cytotoxicity effect in the T98G cell model. TMZ and 17AAG induced a radiation-sensitization effect, respectively. The NFM containing 17AAG or TMZ, known as 17AAG-NFM and TMZ-NFM, enabled cumulative drug release of 34.1% and 39.7% within 35 days. Moreover, 17AAG+TMZ-NFM containing both drugs revealed a synergistic effect in relation to the NFM of a single agent. When combined with radiation, 17AAG+TMZ-NFM induced in an extremely powerful cytotoxic effect. These results confirmed the application of NFM can simultaneously allow multiple treatments to T98G cells. Each modality achieved a significant synergistic effect with the other, leading to a cascading amplification of the therapeutic effect. Due to the superior advantage of sustained drug release over a long period of time, NFM has the promise of clinically addressing the challenge of high recurrence of GBM post-operatively.

Rights: